Prosigna Breast Risk of Recurrence Test

The Prosigna test provides clinicians and patients with genomic insights to help make more informed breast cancer treatment decisions. 

Available to order in the United States starting June 2026.*

For Providers For Patients
Cancer area illustration

PREDICTION THAT ADDS UP

What is the Prosigna Breast test?

The Prosigna Breast ROR test is for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer.

The Prosigna test determines a patient’s Risk of Recurrence (ROR) score and estimates the 10-year probability of distant recurrence.

Inherited Risk Assessment
Screening and Risk Assessment
Diagnosis
Prognosis
Treatment Guidance
Recurrence Monitoring
active woman exercising outside

DID YOU KNOW?

Prosigna is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors into a single Risk of Recurrence (ROR) score and a 10-year probability of distant recurrence.

The test that gets the numbers right

Better inputs = stronger outputs

PAM50

The Prosigna test is based on the PAM50 genomic classifier2,3

10 years

In a clinical study, the Prosigna test proved to be a better predictor of distant recurrence at 5 to 10 years, than other tests4,5

>2/3

of patients with positive nodes may avoid chemotherapy when guided by the Prosigna test1

glowing divider

Real impact on patient care

patient with daughter

I knew there was another genomic test that could provide this information, but I specifically requested the Prosigna test because I wanted to be sure of the accuracy for guiding my treatment decisions.”6

Patient testimonial (pictured with her daughter) Prosigna Breast Risk of Recurrence Test

The breast cancer landscape

Statistics

Globally, breast cancer remains the most common cancer among women.7

  • Breast cancer affects 1 in 88 women in the United States and 1 in 127 women globally.
  • In the US, an estimated 321,910 women and 2,670 men will be diagnosed with invasive breast cancer in 2026.8
  • Among these patients, about 70% will be diagnosed with hormone receptor-positive (HR+) breast cancer.9

Challenges

Choosing the best treatment path is paramount to preventing cancer from coming back.

When breast cancer is caught early and treated appropriately, five-year survival rates reach 92%.10 However, breast cancer can recur up to 20 years later, significantly lowering survival rates.11,12

The Prosigna test, with comprehensive insights and reliable results, identifies patients who may safely avoid chemotherapy – and its toxic long-term side effects. With the Prosigna Breast ROR test, you can confidently choose the optimal treatment pathway.  

The complete formula

The Prosigna test helps guide personalized treatment decisions

The Prosigna test factors a patient’s biological, clinical, and pathological information into a comprehensive report that includes:

  • Risk of Recurrence (ROR) score
  • Probability of 10-year distant recurrence
  • Predicted chemotherapy benefit
  • Intrinsic subtype
  • Proliferation score

Take the next step and learn more about the Prosigna Breast ROR test.

Healthcare provider in a white coat with stethoscope talks to a patient in a bright medical office.
I'm a Healthcare Provider
female patient speaking with female provider about their prosigna ror test results
I'm a Patient or Caregiver

For more information about the Prosigna test available outside of the US

Learn More

References

  1. Stein RC, et al. ASCO. 2026. DOI: 10.1200/JCO.2026.44.16_suppl.500
  2. Perou CM, et al. Nature. 2000. DOI: 10.1038/35021093
  3. Wallden B, et al. BMC Med Genomics. 2015. DOI: 10.1186/s12920-015-0129-6
  4. Dowsett M, et al. J Clin Oncol. 2013. DOI: 10.1200/JCO.2012.46.1558
  5. Sestak I, et al. J Natl Cancer Inst. 2013. DOI: 10.1093/jnci/djt244
  6. Veracyte, Inc. Company data on file. Updated May 2026.
  7. World Cancer Research Fund. Breast cancer statistics. Accessed May 2026.
  8. National Breast Cancer Foundation, Inc. Breast cancer facts & stats. Accessed May 2026.
  9. National Cancer Institute. Cancer stat facts: female breast cancer subtypes. Accessed May 2026.
  10. American Cancer Society. Survival rates for breast cancer. Accessed May 2026.
  11. Breast Cancer Research Association. What to know about breast cancer recurrence. Accessed May 2026.
  12. American Cancer Society. Breast cancer facts & figures 2024-2025. Access May 2026.

Disclaimers

* Prosigna testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York.

The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as an IVD test in territories where registered.

Talk to your doctor about whether Veracyte tests might be right for you.